We have read with careful attention the article, "Methoxyflurane Versus Standard of Care for Acute Trauma-Related Pain in the Emergency Setting: Protocol for a Randomised, Controlled Study in Italy" by Fabbri et al. \[[@CR1]\]. The authors present MEDITA (Methoxyflurane in Emergency Department in ITAly), a Phase IIIb, prospective, randomised, active-controlled, parallel-group, open-label, multicentre trial. We agree with the authors that there is a need for better evidence for the use of methoxyflurane in pain management in the emergency department. Low-dose methoxyflurane was approved based on the STOP! trial, which compared methoxyflurane only to placebo in young patients with acute trauma pain \[[@CR2]\]. Despite a total absence of trials comparing methoxyflurane to an alternative analgesic available in the emergency department, huge efforts are made to introduce methoxyflurane to European emergency physicians, seen as a "global market" as reported in an online promotional video \[[@CR3]\]. Indeed, they consider that methoxyflurane "can fit a very significant market need in terms of getting people out of pain, without them having to take a narcotic on board".

We noticed that the authors will include patients with moderate pain (Numeric Rating Scale 4--6), and that in these patients, guidelines recommend an oral non opioid analgesic that can be given as soon as in the triage room \[[@CR4]\]. Whilst the authors argue that the cost of a morphine treatment is high, we wonder if the authors will include in their analysis the cost and time of preparation and education of the patient for the use of the inhaler, and will compare this to the very cheap and straightforward administration of a pill. A cost-effectiveness analysis does not seem to be planned.

We also question the primary endpoint pain assessment at 10 min. The vast majority of the studies that evaluated pain management in the emergency department had a primary outcome at 30 min, as reported in the evidence-based review from Sin et al. \[[@CR5]\]. Thus, the added value of satisfactory analgesia at 10 min versus 30 min is unclear, and may not be seen as clinically relevant. This highly question the long term effect of methoxyflurane and the need for other antalgic treatment after the single dose of methoxyflurane received.

Finally, in the era of global warming, and following the Katowice Climate Change Conference (24th session of the Conference of the Parties), we believe that we cannot promote a treatment that cause such amount of waste, as the hand-held inhaler must be throw out after usage. Emergency physicians must take an active part in protecting our planet and prescribe other more environment-friendly medications for pain management.

For all these reasons, we strongly believe that we need independent trials if we want to avoid another future medical reversal \[[@CR6]\]. Two trials have been recently funded by the French ministry of health \[[@CR7]\].
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